Alto Neuroscience Net Income
| ANRO Stock | 16.84 1.62 10.64% |
As of the 11th of February 2026, Alto Neuroscience shows the Downside Deviation of 6.34, risk adjusted performance of 0.1187, and Mean Deviation of 4.04. Alto Neuroscience technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices.
Alto Neuroscience's financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Alto Neuroscience's valuation are provided below:We have found one hundred twenty available fundamental signals for Alto Neuroscience, which can be analyzed and compared to other ratios and to its rivals. Self-guided Investors are advised to validate Alto Neuroscience's prevailing fundamentals against the trend between 2010 and 2026 to make sure the company can sustain itself down the road. This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. | Last Reported | Projected for Next Year | ||
| Net Loss | -55.3 M | -52.5 M | |
| Net Loss | -55.3 M | -52.5 M | |
| Net Loss | (2.87) | (3.02) |
Alto | Net Income | Build AI portfolio with Alto Stock |
Evaluating Alto Neuroscience's Net Income across multiple reporting periods reveals the company's ability to sustain growth and manage resources effectively. This longitudinal analysis highlights inflection points, cyclical patterns, and structural changes that short-term snapshots might miss, offering deeper insight into Alto Neuroscience's fundamental strength.
Latest Alto Neuroscience's Net Income Growth Pattern
Below is the plot of the Net Income of Alto Neuroscience over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Alto Neuroscience financial statement analysis. It represents the amount of money remaining after all of Alto Neuroscience operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Alto Neuroscience's Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Alto Neuroscience's overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (61.43 M) | 10 Years Trend |
|
Net Income |
| Timeline |
Alto Net Income Regression Statistics
| Arithmetic Mean | (23,279,141) | |
| Coefficient Of Variation | (90.90) | |
| Mean Deviation | 18,236,889 | |
| Median | (9,187,000) | |
| Standard Deviation | 21,161,138 | |
| Sample Variance | 447.8T | |
| Range | 52.2M | |
| R-Value | (0.82) | |
| Mean Square Error | 153.7T | |
| R-Squared | 0.68 | |
| Significance | 0.000048 | |
| Slope | (3,451,283) | |
| Total Sum of Squares | 7164.7T |
Alto Net Income History
Other Fundumenentals of Alto Neuroscience
Alto Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Alto Neuroscience is extremely important. It helps to project a fair market value of Alto Stock properly, considering its historical fundamentals such as Net Income. Since Alto Neuroscience's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Alto Neuroscience's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Alto Neuroscience's interrelated accounts and indicators.
Click cells to compare fundamentals
Will Pharmaceuticals sector continue expanding? Could Alto diversify its offerings? Factors like these will boost the valuation of Alto Neuroscience. If investors know Alto will grow in the future, the company's valuation will be higher. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Alto Neuroscience data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Understanding Alto Neuroscience requires distinguishing between market price and book value, where the latter reflects Alto's accounting equity. The concept of intrinsic value - what Alto Neuroscience's is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push Alto Neuroscience's price substantially above or below its fundamental value.
Understanding that Alto Neuroscience's value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Alto Neuroscience represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. In contrast, Alto Neuroscience's trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.
Alto Neuroscience 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Alto Neuroscience's stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Alto Neuroscience.
| 11/13/2025 |
| 02/11/2026 |
If you would invest 0.00 in Alto Neuroscience on November 13, 2025 and sell it all today you would earn a total of 0.00 from holding Alto Neuroscience or generate 0.0% return on investment in Alto Neuroscience over 90 days. Alto Neuroscience is related to or competes with Cencora, Regeneron Pharmaceuticals, IDEXX Laboratories, Haleon Plc, Cigna Corp, Elevance Health, and Becton Dickinson. Alto Neuroscience is entity of United States More
Alto Neuroscience Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Alto Neuroscience's stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Alto Neuroscience upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 6.34 | |||
| Information Ratio | 0.1212 | |||
| Maximum Drawdown | 30.37 | |||
| Value At Risk | (8.77) | |||
| Potential Upside | 10.3 |
Alto Neuroscience Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Alto Neuroscience's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Alto Neuroscience's standard deviation. In reality, there are many statistical measures that can use Alto Neuroscience historical prices to predict the future Alto Neuroscience's volatility.| Risk Adjusted Performance | 0.1187 | |||
| Jensen Alpha | 0.8119 | |||
| Total Risk Alpha | 0.1837 | |||
| Sortino Ratio | 0.1078 | |||
| Treynor Ratio | (1.36) |
Alto Neuroscience February 11, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.1187 | |||
| Market Risk Adjusted Performance | (1.35) | |||
| Mean Deviation | 4.04 | |||
| Semi Deviation | 5.42 | |||
| Downside Deviation | 6.34 | |||
| Coefficient Of Variation | 726.81 | |||
| Standard Deviation | 5.64 | |||
| Variance | 31.76 | |||
| Information Ratio | 0.1212 | |||
| Jensen Alpha | 0.8119 | |||
| Total Risk Alpha | 0.1837 | |||
| Sortino Ratio | 0.1078 | |||
| Treynor Ratio | (1.36) | |||
| Maximum Drawdown | 30.37 | |||
| Value At Risk | (8.77) | |||
| Potential Upside | 10.3 | |||
| Downside Variance | 40.14 | |||
| Semi Variance | 29.35 | |||
| Expected Short fall | (4.06) | |||
| Skewness | (0.58) | |||
| Kurtosis | 2.11 |
Alto Neuroscience Backtested Returns
Alto Neuroscience appears to be somewhat reliable, given 3 months investment horizon. Alto Neuroscience secures Sharpe Ratio (or Efficiency) of 0.16, which signifies that the company had a 0.16 % return per unit of risk over the last 3 months. By analyzing Alto Neuroscience's technical indicators, you can evaluate if the expected return of 0.78% is justified by implied risk. Please makes use of Alto Neuroscience's Mean Deviation of 4.04, risk adjusted performance of 0.1187, and Downside Deviation of 6.34 to double-check if our risk estimates are consistent with your expectations. On a scale of 0 to 100, Alto Neuroscience holds a performance score of 12. The firm shows a Beta (market volatility) of -0.56, which signifies possible diversification benefits within a given portfolio. As returns on the market increase, returns on owning Alto Neuroscience are expected to decrease at a much lower rate. During the bear market, Alto Neuroscience is likely to outperform the market. Please check Alto Neuroscience's value at risk, as well as the relationship between the skewness and day median price , to make a quick decision on whether Alto Neuroscience's price patterns will revert.
Auto-correlation | -0.64 |
Very good reverse predictability
Alto Neuroscience has very good reverse predictability. Overlapping area represents the amount of predictability between Alto Neuroscience time series from 13th of November 2025 to 28th of December 2025 and 28th of December 2025 to 11th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Alto Neuroscience price movement. The serial correlation of -0.64 indicates that roughly 64.0% of current Alto Neuroscience price fluctuation can be explain by its past prices.
| Correlation Coefficient | -0.64 | |
| Spearman Rank Test | -0.36 | |
| Residual Average | 0.0 | |
| Price Variance | 0.96 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Alto Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, Alto Neuroscience reported net income of (61.43 Million). This is 118.0% lower than that of the Pharmaceuticals sector and 187.7% lower than that of the Health Care industry. The net income for all United States stocks is 110.76% higher than that of the company.
Alto Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Alto Neuroscience's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Alto Neuroscience could also be used in its relative valuation, which is a method of valuing Alto Neuroscience by comparing valuation metrics of similar companies.Alto Neuroscience is currently under evaluation in net income category among its peers.
Alto Neuroscience ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Alto Neuroscience's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Alto Neuroscience's managers, analysts, and investors.Environmental | Governance | Social |
Alto Fundamentals
| Return On Equity | -0.45 | ||||
| Return On Asset | -0.24 | ||||
| Current Valuation | 412.86 M | ||||
| Shares Outstanding | 31.07 M | ||||
| Shares Owned By Insiders | 6.43 % | ||||
| Shares Owned By Institutions | 66.15 % | ||||
| Number Of Shares Shorted | 2.17 M | ||||
| Price To Book | 4.69 X | ||||
| EBITDA | (68.61 M) | ||||
| Net Income | (61.43 M) | ||||
| Total Debt | 16.94 M | ||||
| Book Value Per Share | 4.11 X | ||||
| Cash Flow From Operations | (47.42 M) | ||||
| Short Ratio | 5.51 X | ||||
| Earnings Per Share | (2.30) X | ||||
| Target Price | 31.13 | ||||
| Number Of Employees | 76 | ||||
| Beta | 2.85 | ||||
| Market Capitalization | 523.16 M | ||||
| Total Asset | 177.54 M | ||||
| Retained Earnings | (138.4 M) | ||||
| Working Capital | 159.33 M | ||||
| Net Asset | 177.54 M |
About Alto Neuroscience Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Alto Neuroscience's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Alto Neuroscience using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Alto Neuroscience based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Alto Neuroscience
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Alto Neuroscience position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Alto Neuroscience will appreciate offsetting losses from the drop in the long position's value.Moving against Alto Stock
| 0.72 | PSGTF | PT Semen Indonesia | PairCorr |
| 0.48 | HPQ | HP Inc Aggressive Push | PairCorr |
| 0.41 | MMM | 3M Company | PairCorr |
| 0.32 | IBM | International Business | PairCorr |
The ability to find closely correlated positions to Alto Neuroscience could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Alto Neuroscience when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Alto Neuroscience - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Alto Neuroscience to buy it.
The correlation of Alto Neuroscience is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Alto Neuroscience moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Alto Neuroscience moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Alto Neuroscience can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out To learn how to invest in Alto Stock, please use our How to Invest in Alto Neuroscience guide.You can also try the Watchlist Optimization module to optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm.
Will Pharmaceuticals sector continue expanding? Could Alto diversify its offerings? Factors like these will boost the valuation of Alto Neuroscience. If investors know Alto will grow in the future, the company's valuation will be higher. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Alto Neuroscience data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Understanding Alto Neuroscience requires distinguishing between market price and book value, where the latter reflects Alto's accounting equity. The concept of intrinsic value - what Alto Neuroscience's is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push Alto Neuroscience's price substantially above or below its fundamental value.
Understanding that Alto Neuroscience's value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Alto Neuroscience represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. In contrast, Alto Neuroscience's trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.